Dry mouth was the most commonly reported adverse event ( AE ) in the fesoterodine groups ( placebo group , 3.4 % ; fesoterodine 4-mg group , 12.9 % ; fesoterodine 8-mg group , 26.1 % ) ; most cases were mild or moderate in all treatment groups .